Mostrar 1 - 3 resultats de 3 per cerca 'Pascal Do', hora de la petició: 0.03sec Refinar resultats
  1. 1
    Safety of combined PD‐1 pathway inhibition and radiation therapy for non‐small‐cell lung cancer: A multicentric retrospective study from the GFPC

    Safety of combined PD‐1 pathway inhibition and radiation therapy for non‐small‐cell lung cancer: A multicentric retrospective study from the GFPC per Paul Lesueur, Alexandre Escande, Juliette Thariat, Enora Vauléon, Isabelle Monnet, Alexis Cortot, Delphine Lerouge, Serge Danhier, Pascal Dô, Catherine Dubos‐Arvis, Christos Chouaïd, Radj Gervais

    Publicat 2018-11-01
    Obtenir text complet
    Article
  2. 2
    Management and outcomes of non–small cell lung cancer patients with rapid progression under second‐or‐more‐line immune checkpoint inhibitors: ERORECI study (GFPC 2016‐04)

    Management and outcomes of non–small cell lung cancer patients with rapid progression under second‐or‐more‐line immune checkpoint inhibitors: ERORECI study (GFPC 2016‐04) per Alain Vergnenegre, Margaux Geier, Florian Guisier, Regine Lamy, Bénédicte Comet, Gwenaelle Le Garff, Pascal Do, Henri Janicot, Hugues Morel, Chantal Decroisette, Michel Andre, Lionel Falchero, Nicolas Paleiron, Isabelle Monnet, the GFPC Team

    Publicat 2020-01-01
    Obtenir text complet
    Article
  3. 3
    Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients

    Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients per Jacques Cadranel, Alexis B. Cortot, Hervé Lena, Bertrand Mennecier, Pascal Do, Eric Dansin, Julien Mazieres, Christos Chouaid, Maurice Perol, Fabrice Barlesi, Gilles Robinet, Sylvie Friard, Luc Thiberville, Clarisse Audigier-Valette, Alain Vergnenegre, Virginie Westeel, Khemaies Slimane, Alexandru Buturuga, Denis Moro-Sibilot, Benjamin Besse

    Publicat 2018-02-01
    Obtenir text complet
    Article

Eines de cerca: